Sol-Gel rises on FDA approval of skin disease cream

SOL-GEL TECHNOLOGIES

25/04/2022 12:26

** Shares of skin disease drug developer Sol-Gel
Technologies  SLGL.O  rise 17.6% to $8.66 premarket
    ** Co says U.S. FDA has approved its epsolay topical cream
for treatment of rosacea, a condition that causes reddened skin
and pimples, usually affecting the face (https://refini.tv/3K6WCNW)
    ** Sol-Gel has granted to Galderma Holding SA the exclusive
rights to commercialize epsolay in the Unites States
    ** SLGL says treatment is covered by granted patents until
2040
    ** SLGL had fallen 0.54% YTD, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))